OZEM vs. GNOM

Last updated Jun 5, 2026

OZEM (Roundhill Glp-1 & Weight Loss ETF) and GNOM (Global X Genomics & Biotechnology ETF) are both Health & Biotech Equities funds. OZEM is actively managed, while GNOM is passively managed. Over the past year, OZEM returned 22.50% vs 57.90% for GNOM. A 0.61 correlation means they provide meaningful diversification when combined. OZEM charges 0.59%/yr vs 0.50%/yr for GNOM.

Performance

OZEM vs. GNOM - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Roundhill Glp-1 & Weight Loss ETF (OZEM) and Global X Genomics & Biotechnology ETF (GNOM). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, OZEM achieves a -9.51% return, which is significantly lower than GNOM's 11.56% return.

OZEM

• 1D: 2.77%
• 1M: -2.00%
• YTD: -9.51%
• 6M: -3.76%
• 1Y: 22.50%
• 3Y*: —
• 5Y*: —
• 10Y*: —

GNOM

• 1D: 3.47%
• 1M: 11.33%
• YTD: 11.56%
• 6M: 9.34%
• 1Y: 57.90%
• 3Y*: 0.45%
• 5Y*: -9.59%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

OZEM vs. GNOM - Yearly Performance Comparison

	2026 (YTD)	2025	2024
OZEM Roundhill Glp-1 & Weight Loss ETF	-9.51%	41.87%	-3.78%
GNOM Global X Genomics & Biotechnology ETF	11.56%	18.65%	-9.17%

Correlation

The correlation between OZEM and GNOM is 0.66, which is moderate. They share some common price drivers but move independently often enough to provide real diversification benefit when combined.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.66
Correlation (All Time) Calculated using the full available price history since May 22, 2024	0.62

The correlation between OZEM and GNOM has been stable across timeframes, ranging from 0.61 to 0.66 - a consistent structural relationship.

OZEM vs. GNOM - Sectors Allocation Comparison

Sectors	OZEM	GNOM
Healthcare	100.0%	99.6%
Financial Services	0.1%	-
Basic Materials	-	-
Communication Services	-	-
Consumer Cyclical	-	-
Consumer Defensive	-	-
Energy	-	-
Industrials	-	-
Real Estate	-	-
Technology	-	0.4%
Utilities	-	-

Return for Risk

OZEM vs. GNOM — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

OZEM

OZEM Risk / Return Rank: 25
OZEM Sharpe Ratio Rank: 26
OZEM Sortino Ratio Rank: 27
OZEM Omega Ratio Rank: 26
OZEM Calmar Ratio Rank: 25
OZEM Martin Ratio Rank: 21

GNOM

GNOM Risk / Return Rank: 62
GNOM Sharpe Ratio Rank: 67
GNOM Sortino Ratio Rank: 68
GNOM Omega Ratio Rank: 58
GNOM Calmar Ratio Rank: 66
GNOM Martin Ratio Rank: 54

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

OZEM vs. GNOM - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Roundhill Glp-1 & Weight Loss ETF (OZEM) and Global X Genomics & Biotechnology ETF (GNOM). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	OZEM	GNOM	Difference
Sharpe ratio: Return per unit of total volatility	0.92	2.18	-1.26
Sortino ratio: Return per unit of downside risk	1.41	3.06	-1.65
Omega ratio: Gain probability vs. loss probability	1.17	1.35	-0.18
Calmar ratio: Return relative to maximum drawdown	1.18	3.20	-2.02
Martin ratio: Return relative to average drawdown	2.43	9.21	-6.78
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

OZEM vs. GNOM - Sharpe Ratio Comparison

The current OZEM Sharpe Ratio is 0.92, which is lower than the GNOM Sharpe Ratio of 2.18. The chart below compares the historical Sharpe Ratios of OZEM and GNOM, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	OZEM	GNOM	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.92	2.18	-1.26
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	-0.29	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.44	-0.07	+0.51

Drawdowns

OZEM vs. GNOM - Drawdown Comparison

The maximum OZEM drawdown since its inception was -28.65%, smaller than the maximum GNOM drawdown of -75.00%. Use the drawdown chart below to compare losses from any high point for OZEM and GNOM.

Drawdown Indicators

	OZEM	GNOM	Difference
Max Drawdown Largest peak-to-trough decline	-28.65%	-75.00%	+46.35%
Max Drawdown (1Y) Largest decline over 1 year	-19.16%	-18.17%	-0.99%
Max Drawdown (3Y) Largest decline over 3 years	—	-46.47%	—
Max Drawdown (5Y) Largest decline over 5 years	—	-72.29%	—
Current Drawdown Current decline from peak	-16.48%	-53.90%	+37.42%
Average Drawdown Average peak-to-trough decline	-8.92%	-40.56%	+31.64%
Ulcer Index Depth and duration of drawdowns from previous peaks	9.28%	6.30%	+2.98%

Volatility

OZEM vs. GNOM - Volatility Comparison

The current volatility for Roundhill Glp-1 & Weight Loss ETF (OZEM) is 6.35%, while Global X Genomics & Biotechnology ETF (GNOM) has a volatility of 8.77%. This indicates that OZEM experiences smaller price fluctuations and is considered to be less risky than GNOM based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	OZEM	GNOM	Difference
Volatility (1M) Calculated over the trailing 1-month period	6.35%	8.77%	-2.42%
Volatility (6M) Calculated over the trailing 6-month period	17.31%	19.72%	-2.41%
Volatility (1Y) Calculated over the trailing 1-year period	24.60%	26.66%	-2.06%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	25.08%	33.61%	-8.53%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	25.08%	34.19%	-9.11%

OZEM vs. GNOM - Expense Ratio Comparison

OZEM has a 0.59% expense ratio, which is higher than GNOM's 0.50% expense ratio.

Dividends

OZEM vs. GNOM - Dividend Comparison

OZEM's dividend yield for the trailing twelve months is around 1.33%, more than GNOM's 1.23% yield.

Position	TTM	2025	2024	2023	2022	2021	2020
GNOM Global X Genomics & Biotechnology ETF	1.23%	1.37%	0.00%	0.00%	0.00%	0.03%	0.14%
OZEM Roundhill Glp-1 & Weight Loss ETF	1.33%	1.20%	0.22%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions

Can I hold both OZEM and GNOM in my portfolio?

OZEM and GNOM have a correlation of 0.66, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, OZEM or GNOM?

GNOM has higher volatility (8.77%) compared to OZEM (6.35%). In terms of maximum drawdown, OZEM dropped -28.65% vs GNOM's -75.00%.

Which ETF is better, OZEM or GNOM?

On 1-year performance, GNOM leads with 57.90% vs 22.50% for OZEM. On fees, GNOM is cheaper at 0.50% per year. On volatility, OZEM has been the lower-risk option at 6.35%. The better choice depends on whether you care most about return, fees, risk, or income.

Which ETF has performed better, OZEM or GNOM?

Over the 1-year period, GNOM has performed better with a 57.90% return vs 22.50%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.

Which ETF is cheaper, OZEM or GNOM?

GNOM is cheaper with a 0.50% expense ratio, compared with 0.59% for OZEM.

Which ETF pays a higher dividend yield, OZEM or GNOM?

OZEM has the higher dividend yield at 1.33%, compared with 1.23% for GNOM.

What is the main difference between OZEM and GNOM?

They also come from different issuers: Roundhill and Global X. Their fees differ too: 0.59% for OZEM and 0.50% for GNOM.

Which has better risk-adjusted returns?

GNOM currently has the higher Sharpe Ratio (2.18 vs 0.92), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.